1. Ex-FDA Chief Gottlieb says regulator needs to up pace on COVID-19 drugs— Gilead won't be charging for use of experimental COVID drug, for now — FDA backs first emergency COVID-19 antibody test from Cellex — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

New low for pharma industry

Discussion in 'Vivus Pharmaceuticals' started by Anonymous, Mar 30, 2015 at 4:22 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    I have never seen such a lack of respect for a sales team as PDi and Vivus .Complete ASSHOLES!!!!

  2. Anonymous

    Anonymous Guest

    Wow can't believe they treat people like shit !!
  3. Anonymous

    Anonymous Guest

    I'm glad to be out of this shit hole!! I will take my sales with me, the truth will kill this shity company.
  4. Anonymous

    Anonymous Guest

    I hope those few remaining and retained reps see how Vivus treated the reps and realize your time is numbered. I hope the stockholders see that Seth has no true plan or vision and cast their votes with selling this POS stock.
  5. Anonymous

    Anonymous Guest

    I wonder how those reps who they reposted their positions feel about this article?
    One of the pureyors of the newest weight-loss drugs is going on a diet.

    Vivus , which sells the Qsymia pill, plans to trim its U.S. sales force by about one-third to approximately 100 sales reps, down from 150. At the same time, the drug maker plans to shift some of its spending to “high-value, consumer-focused digital media projects” to support obesity education, according to a statement.

    The move comes as the drug maker struggles to make its prescription drug stand out among a trio of recent entrants. Over the past 20 weeks, the number of new U.S. prescriptions written for the Vivus pill has remained flat, according to RBC Capital Markets analyst Simos Simeonidis, who cited data from IMS Health and Symphony Health, two different market research firms.

    Moreover, Qsymia market share also trails those two rival drugs – Contrave, which is sold by Orexigen Therapeutics and Takeda Pharmaceuticals , and Belviq, which is marketed by Arena Pharmaceuticals and Eisai. Using data from Symphony Health, for instance, the Vivus pill has captured 24% of the U.S. market, while the Orexigen drug has 32% and the Arena pill has nearly 44%.